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We have examined sensitivity and specificity of pseudocontinuous arterial spin labeling (PCASL) to
detect global and regional changes in cerebral blood flow (CBF) in response to two different
psychoactive drugs. We tested alcohol and morphine in a placebo-controlled, double-blind
randomized study in 12 healthy young men. Drugs were administered intravenously. Validated
pharmacokinetic protocols achieved minimal intersubject and intrasubject variance in plasma drug
concentration. Permutation-based statistical testing of a mixed effect repeated measures model
revealed a widespread increase in absolute CBF because of both morphine and alcohol.
Conjunction analysis revealed overlapping effects of morphine and alcohol on absolute CBF in
the left anterior cingulate, right hippocampus, right insula, and left primary sensorimotor areas.
Effects of morphine and alcohol on relative CBF (obtained from z-normalization of absolute CBF
maps) were significantly different in the left putamen, left frontoparietal network, cerebellum, and
the brainstem. Corroborating previous PET results, our findings suggest that PCASL is a promising
tool for central nervous system drug research.
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Introduction
One of the main objectives in central nervous system
(CNS) drug development is to identify global and
regional effects of drugs on the brain, and to establish
a link between these factors and the clinical out-
comes. Global change in cerebral blood flow (CBF)
is an important marker of cerebral autoregulation
(Heiss and Podreka, 1978), whereas the regional
distribution of CBF might reflect drug effects on
functional brain activity. Initially,
15O-PET was used
to detect drug effects on cerebral circulation (Ito et al,
1999; Volkow et al, 1988). However, replication and
repetition of positron emission tomography (PET)
studies is costly and not widely available. Besides
cost and availability, drawbacks include radiation
hazards that prohibit repeated measurements within
the same subject over short periods of time. Yet, the
ability to perform repeated measurements provides
opportunity for better characterization of concentra-
tion-dependent drug effects and placebo by time
interaction effects. Therefore, research in magnetic
resonance imaging techniques for perfusion imaging,
such as arterial spin labeling (ASL), aims to offer an
advantageous alternative to PET for clinical pharma-
cology (Detre et al, 2009).
Perfusion imaging allows a quantitative measure-
ment of the CBF based on the movement of
magnetically labeled endogenous water molecules
of the arterial blood. In the last few years, the
introduction of clinical medium field magnetic
resonance imaging scanners (3T), background
suppression, and improved labeling schemes
based on a pulsed version of continuous ASL
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to maturation of ASL. Current implementations
enable whole-brain perfusion imaging including the
cerebellum at a resolution higher than 3 3 7mm
3
within 5minutes (Dai et al, 2008; van Osch et al,
2009). Recent studies have characterized the physio-
logical basis of perfusion functional magnetic reso-
nance imaging (fMRI) signal and have established its
concordance with CBF measurement using oxygen-
15 positron emission tomography (
15O-PET) (Bokkers
et al, 2009; Detre et al, 2009).
In this study, we have examined the applicability
of PCASL in pharmacological research by performing
repeated PCASL measurements of the ‘resting-state’
perfusion in a randomized, placebo-controlled study
of the effects of alcohol and morphine on CBF. The
reason for choosing two substances is to examine
PCASL’s sensitivity beyond nonspecific changes in
circulation that result from physiological effects of
these drugs. For PCASL to be applicable for pharma-
cological research, it has to be sensitive to minute
and regional changes in brain areas where the drugs
act, above the general physiological effects.
As the first step in exploring the usefulness of
PCASL for pharmacological CNS research, we chose
alcohol and morphine. Alcohol and morphine are
two well-characterized substances in psychoactive
drug studies with both overlapping and distinct
effects. Both alcohol (Blaha et al, 2003; Luksch et al,
2009; Sano et al, 1993) and morphine or similar
opiate drugs are vasodilators, and increase global
cerebral perfusion (Kofke et al, 2007; MacIntosh et al,
2008). Both alcohol and morphine induce euphoric
and sedative effects. Several studies have shown that
both alcohol and morphine alter brain activity in
regions such as cingulate cortex, insula, somatosen-
sory, and motor cortices, as well as hippocampus,
basal ganglia, cerebellum, and brainstem, which are
associated with behavioral and physiological effects
of these drugs. (See Supplementary Table for refer-
ence to previous studies.) However, whereas mor-
phine effects are primarily coupled to regional
binding potential for m-opioid receptors (Baumgart-
ner et al, 2006; Zubieta et al, 2001), alcohol (ethanol)
primarily targets a subunit of GABAA receptors
(Hanchar et al, 2006), causes a global suppression
of glucose metabolism (de Wit et al, 1990; Volkow
et al, 2008), and affects widespread neuroendocrine
and neurotransmitter systems throughout the brain,
including dopaminergic, serotonergic, and even
opiate neurotransmitter systems (Koob et al, 1998).
This raises the question whether PCASL is able to
identify overlapping and distinct drug effects that
corroborate existing PET findings.
Another reason for starting with these substances
is because we have developed and validated infusion
protocols based on pharmacokinetic models for each
of these drugs (Sarton et al, 2000; Zoethout et al,
2008), which enable us to achieve pseudo-steady
plasma concentration levels of each drug for
prolonged periods, thereby minimizing the intersub-
ject and intrasubject pharmacokinetic variations and
allowing for equilibration of drug concentrations in
the brain. Thus, examining the effect of these drugs
on regional cerebral perfusion in the same subject,
without any task or perceptual condition, helps
answer an important question about the substance
specificity of the effects measured by PCASL. We
examine drug effects on the global average CBF, and
provide statistical maps of regional distribution of
CBF across the brain (absolute CBF), and regional
changes in relative CBF (rCBF; z-normalized to the
global average). Although related, these various
metrics provide complementary information about
effects of drugs on systemic physiological effects
(from global mean perfusion and absolute CBF
distribution), and about interaction between differ-
ent regions about global effects (from rCBF), which
might be linked to adaptive brain function. These
effects will be further examined in post hoc region of
interest analyses to quantify the effects and illustrate
the extent of between- and within-subject variances
across time and experimental sessions.
Materials and Methods
Subjects
A total of 12 healthy male participants (age 18 to 40 years)
volunteered for a randomized double-dummy, double-
blind, placebo-controlled study involving three visits (each
1 week apart). Exclusion criteria included any kind of
implants, pacemakers, or prothesis; any history of medical
disorders that pose risk to subjects (e.g. opioid allergy,
positive hepatitis B, C or HIV, cardiac or vascular disorder;
asthma or pulmonary disease, major gastrointestinal
abnormalities, peptic ulceration, hepatic, neurological,
psychiatric, hematological, endocrine, renal, or major
genitourinary disease) or jeopardize the aim of the study
by introducing confounds (e.g. prevalence of illicit drug
usage, daily consumption of more than four alcoholic
beverages, cigarette smoking, heavy caffeine dependency,
and irregular diurnal rhythm).
Drug Infusion
All drug and placebo sessions were randomized. During
each visit, subjects experienced identical experimental
procedures but in each session, different drug compounds
were administered. Placebo occasions consisted of a sham
procedure using a glucose 5% solution, including compu-
ter-driven adaptations of infusion rates and breath alcohol
measurements.
We used a breath alcohol clamping method paradigm
that provides accurate stable levels of alcohol (O’Connor
et al, 1998), as previously shown (Zoethout et al, 2008).
We aimed for maintaining alcohol levels at 0.6g/L for
90minutes. Alcohol concentrations were controlled based
on an intravenous ethanol clamping paradigm using
ethanol 10% in glucose 5% (Zoethout et al, 2008).
To minimize infusion pain, alcohol placebo occasions
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solution, including computer-driven adaptations of infu-
sion rates and breath alcohol measurements. Infusion rates
required to maintain stable alcohol levels were computed
by a nonblind staff member without any other involvement
in the study, based on measurements of breath alcohol at
5minute intervals between 0 and 30minutes, at 10minute
intervals between minutes 30 and 60, and 30minute
intervals between minutes 60 and 300 after the start of
the placebo or drug administration.
Morphine infusion was conducted according to pharma-
cokinetic models established earlier (Sarton et al, 2000). To
reach stable serum levels of morphine (80nmol/L), an
initial bolus of 100mg/kg/h was infused during 1minute,
followed by a continuous infusion of 30mg/kg/h for
2.5hours. Total volume of morphine infusion was
B14.5mg—a safe dose within the therapeutic range of
intravenous morphine for acute pain. To determine the
plasma concentration of morphine, venous blood was
collected in 5mL plain tubes (Becton and Dickinson and
company, Franklin Lakes, NJ, USA). Blood samples were
taken at 0, 15, 30, 50, 60, 90, 120, 150, 180, 210 and
270minutes after the start of the placebo or drug adminis-
tration. All samples were centrifuged for 10minutes at 2000
G between 30 and 45minutes after collection. Next, plasma
samples were stored at  211C. Plasma concentrations of
morphine were determined using liquid chromatography
with tandem mass spectrometry (Sarton et al, 2000).
Pharmacodynamic Assessments
Computerized visual analog scales (VASs) were
used to determine whether drugs induced measurable
subjective CNS effects. All VASs were performed once at
baseline and were repeated at 30, 60, 90, and 120minutes
after the start of infusion. The VAS Bond and Lader (Bond
and Lader, 1974) was used for the subjective assessment of
the state of mind at that moment. Three factors correspond-
ing to ‘alertness’, ‘mood’, and ‘calmness’ can be derived
from the VAS Bond and Lader. The VAS Bond and Lader
scores are expressed in millimeter (mm), in which 50mm
indicates a normal feeling. We also used VAS nausea and
VAS feeling drunk, each consisting of a single scale in
which the extreme left side (0mm) corresponds to, for
instance, ‘not nauseous at all’ and the extreme right side
(100mm) to ‘maximum nauseous’. Subjects were asked to
indicate a single point on the scale, reflecting their amount
of nausea.
Physiological data were measured during scanning using
the standard scanner equipment. We averaged the heart rate
over the period of each scan (B4minutes). The respiratory
signal over the scanning period was Fourier –transformed,
and the highest harmonic was used as representative of the
average respiration rate during the scan.
Image Acquisition and Processing
A 3T Achieva scanner (Philips Medical System, Best, the
Netherlands) was used for image acquisition. The PCASL
acquisitions were part of a larger resting-state fMRI study
that will be reported elsewhere (Khalili-Mahani et al,
2011).
The CBF was measured using PCASL (Dai et al, 2008; van
Osch et al, 2009) immediately before and 120minutes after
drug injection began. A total of 30 pairs of perfusion-
weighted and control scans (single shot echo planar imaging
(EPI), 17 slices of 7mm with an in-plane resolution of
3 3mm
2, sensitivity-encoded (SENSE) factor 2.5, time of
echo (TE)=13.9ms at a delay of 1525ms, slice time 35ms)
were obtained (total scan time of 4minutes 10seconds). Data
for each subject was inspected visually to rule out deleterious
intraacquisition motion artifacts. For each subject, we
obtained six PCASL data sets (Placebopre, Placebopost,
Morphinepre,M o r p h i n e post,A l c o h o l pre, and Alcoholpost). For
each set, voxelwise CBF was computed using
CBFðx; y; zÞ¼
P N
t¼1
ðScontrolðx; y; z; tÞ Slabelðx; y; z; tÞÞ
N
 
1
labefficiency M0 T1blood l
 e
delayþslice timeðz 0:5Þ
T1blood þ TE
T2
  
where N=30, l=0.76, lab efficiency=0.85, TE=13.9ms,
T2=50ms,andT1blood=1680ms. These computations were
performed using MATLAB R2009.a (Mathworks). Data
orientation was preserved by using a MATLAB nifti-reader
tool (http://www.rotman-baycrest.on.ca/~jimmy/NIfTI/, Rot-
man Research Institute, Toronto, ON, Canada).
Having computed CBF in native space for each subject,
we spatially standardized them to the MNI152 template
(Montreal Neurological Institute, Montreal, QC, Canada) to
be able to do group-level statistical inference testing.
Spatial standardization involved generating an unbiased
CBF template for every subject by first, a rigid body
registration using FMRIB’s Linear Image Registration Tool
(FLIRT, with 6 degrees of freedom, based on reducing the
least square cost function, and resampling with trilinear
interpolation) of each image to the other 5 images in the
series; and next, generating the template by averaging the
30 resulting images. This subject template was then
registered to the MNI152 template (Montreal Neurological
Institute) using FLIRT, with six degrees of freedom, based on
reducing the least square cost function, and under sampled
to 2mm isotropic resolution with trilinear interpolation. The
resulting transformation matrix was used to align all
individual CBF maps to the MNI152 space. A 5mm blurring
kernel was used to smooth the resulting CBF maps. The
resulting absolute CBF maps were masked with an eroded
standard MNI152 brain mask.
After spatial standardization, we defined three metrics:
global mean CBF (averaged over the spatially registered
brain volume), absolute CBF (which is the spatially
normalized CBF maps obtained above), and rCBF maps
(obtained by voxelwise z-transformation of each one of the
72 absolute CBF maps with respect to its own global mean
and its own standard deviation (s.d.). This produced
normalized CBF maps whose global mean and s.d.
(computed across the whole-brain volume) were 0 and 1,
respectively. The areas of high Z amplitude (whether
positive or negative) indicate regions where CBF exceeds
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rCBF maps are complimentary: the first test allows
localizing areas where highest changes in CBF (while
accounting for repetitions across time and subject) occur;
and the latter allows identifying changes in perfusion
distribution across the brain in relation to global mean CBF.
Statistical analysis was performed on these absolute and
rCBF maps. In all stages, Functional Magnetic Resonance
Imaging of the Brain (FMRIB) Software Library (FSL 4.0,
Oxford, UK; http://www.fmrib.ox.ac.uk/fsl) was used.
Statistical Analysis
Repeatedly measured pharmacodynamic data (3 treatments 
5 times 12 subjects) were compared with a mixed model
analysis of variance with fixed factors treatment, time, and
treatment by time and random factor subject, subject by
treatment, and subject by time and the average prevalue
(average over all measurements at or before time=0) as
covariate (SAS for windows V9.1.2; SAS Institute, Cary,
NC, USA). Related graphs of these data were drawn with
Prism 4.0 (Graphpad Software, La Jolla, CA, USA).
To avoid assumptions about normal distribution of the
data, analysis of variance for repeated measures of global
mean CBF (3 treatments 2 times 12 subjects) was
conducted nonparametrically using Friedman’s test with
Dunn’s correction for multiple comparisons.
Regional changes in CBF were determined nonparame-
trically. Permutation-based statistical inference (Nichols
and Holmes, 2002; 5000 permutation tests) was used in a
triple t-test, examining effect of each drug over time,
compared with placebo, on absolute and rCBF. Statistical
significance was set at P<0.05, after cluster-based correc-
tion for familywise errors (based on the null distribution of
the max cluster size with cluster-defining threshold of
t=3.2, across the entire brain) (Worsley et al, 1992).
In the Supplementary Materials, we also provide a
description of the effects associated with post versus pre
(importantly placebo) at uncorrected P-values <0.05.
Region of Interest Quantification of CBF Changes
To quantify CBF changes under each treatment within
statistically significant clusters, we computed the difference
of the ratio of absolute CBF within the region of interest
(ROI) about global mean at each time point: DCBFROI=abso-
lute CBFROI (post) absolute CBFROI (pre) and DrCBFROI=(abso-
lute CBFROI (post)/global CBFpost) (absolute CBFROI (pre)/global
CBFpre). These computations provide a numerical estimate of
the CBF effect sizes that satisfied the criteria for statistical
significance of the tested model, and help understanding
and interpretation of the regional effects.
Effects of Physiological Factors on CBF Maps
It has been shown that altered respiration because of opiate
treatment leads to a hypercapnic-related increase in CBF
(MacIntosh et al, 2008; Pattinson et al, 2007). Also, heart rate
increase because of alcohol might be associated with
vasoreactive changes that alter the arterial blood flow velocity
(Blaha et al, 2003). Because respiration (after morphine
administration) and heart rate (after alcohol and placebo)
were significantly affected by treatment, their effect on global
mean and regional absolute CBF was examined.
First, regression analysis was performed to determine
how much of variation in the global mean CBF was
explained by heart and respiration rates. Second, effects
of respiration and heart rate variations on the topography
of the absolute CBF changes were tested by including a
demeaned vector of both respiration and heart rate in the
statistical models tested above.
Results
Pharmacokinetic Profiles
Figure 1 illustrates the individual pharmacokinetic
profiles. At the time of posttreatment scan, average
morphine levels were at 68.04±8.8nmol/L and
average alcohol levels were at 0.63±0.038 (g/L).
Pharmacodynamic Effects
Table 1 summarizes the results of the mixed model
analysis of variance of the pharmacodynamic effects.
Figure 1 Pharmacokinetic profiles in the 12 individuals. Plasma
concentration of morphine (top) and alcohol (bottom). The
vertical bars correspond to when the pseudocontinuous arterial
spin labeling images were acquired.
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creased calmness and feeling of nausea, and reduced
respiration rate and heart rate. There was a trend
for reduced alertness after morphine admini-
stration compared with placebo. Compared with
placebo, alcohol treatment increased the drunken-
ness feeling and heart rate. Compared with baseline,
heart rate significantly decreased after placebo
treatment.
Effects of Drug on Global and Regional CBF
Effects on global CBF: As the significant decrease in
heart rate after placebo might be related to experien-
cing stress because of novelty and unpredictability of
the experiment, we first ensured that there was no
significant effects of visit order (S(12,3)=0.67,
P>0.7, Figure 2A) versus treatment session
(S(12,3)=0.167, P>0.9, Figure 2B) on baseline (i.e.,
preinfusion) average CBF values.
Figure 2C illustrates intersubject variations in
DCBF=global mean CBFpost global mean CBFpre.
Friedman’s test revealed a significant drug by
time interaction effect on DCBF (S(12,3)=16.7,
P<0.0005). Morphine treatment increased CBF in
11/12 subjects (95% confidence interval (CI): 4.7 to
11.1/100mltissue/min), and placebo treatment
decreased CBF in 11/12 subjects (95% CI:  2.8 to
 4.3/100mltissue/min); CBF increase after alcohol
was present in only half of the subjects (95%
CI: 2.5 to 7.1/100mltissue/min) and the other
half showed a mild decrease (95% CI:  0.3 to
 3.4/100mltissue/min).
Table 1 Pharmacodynamic effects
Parameter LS means Treatment
P-value
LS mean contrast 95% CI (lower, upper)
Placebo Alcohol Morphine Alcohol vs
placebo
Morphine vs
placebo
Morphine vs
alcohol
VAS alcohol effects (mm) 1.7 19.1 7.2 0.0096 17.4 (6.7, 28.2) 5.5 ( 5.1, 16.2)  11.9 ( 22.7,  1.1)
P=0.003 P=0.291 P=0.032
VAS alertness (mm) 48.6 46.0 43.7 0.1843  2.6 ( 8.0, 2.8)  5.0 ( 10.3, 0.4)  2.3 ( 7.7, 3.0)
P=0.324 P=0.069 P=0.374
VAS calmness (mm) 53.4 58.2 60.6 0.0428 4.7 ( 1.5, 11.0) 7.2 (1.6, 12.7) 2.5 ( 3.3, 8.2)
P=0.132 P=0.014 P=0.386
VAS mood (mm) 51.7 52.8 54.4 0.5171 1.1 ( 4.1, 6.2) 2.8 ( 2.2, 7.8) 1.7 ( 3.4, 6.7)
P=0.662 P=0.262 P=0.498
VAS nausea (mm) 3.7 3.0 18.6 0.0320  0.6 ( 13.5, 12.2) 14.9 (2.1, 27.8) 15.6 (2.8, 28.4)
P=0.918 P=0.025 P=0.020
Heart rate (bpm) 55.5 60.7 51.7 0.0004 5.2 (1.4, 9.0)  3.8 ( 7.5,  0.0)  9.0 ( 12.7,  5.2)
P=0.010 P=0.049 P<0.0001
Respiration rate (m) 16.6 16.6 13.0 <0.0001 0.0 ( 1.4, 1.4)  3.6 ( 5.0,  2.2)  3.6 ( 5.0,  2.2)
P=0.966 P<0.0001 P<0.0001
Cerebral blood flow 9.09 10.46 11.59 <0.0001 1.37 (0.56, 2.18) 2.49 (1.69, 3.30) 1.13 (0.32, 1.94)
(ml/100ml tissue/min) P=0.002 P<0.0001 P=0.009
CI, confidence interval; LS, least square; VAS, visual analog scale.
Figure 2 Interindividual variations in pretreatment and posttreatment global mean cerebral blood flow (CBF). (A) Effects of visit on the
baseline global mean CBF are not significant; (B) effects of session on baseline global mean CBF are not significant; and (C) the treatment
e f f e c to nC B Fc h a n g ef r o mb a s e l i n ei ss i g n i f i c a n ta n dal a r g ed e g r e eo f interindividual variance is present after the alcohol treatment.
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and relative CBF: Spatial distribution of increase in
absolute CBF because of morphine and alcohol is
illustrated in Figures 3A and 3B. Maps show the
t-values of comparing Drugpost pre versus Placebopost pre
within the significant clusters (corrected P<0.05) for
each drug. These tests indicate a broad increase in the
absolute CBF across the brain. Because of the wide-
spread effect of these drugs on perfusion, our cluster
correction criteria did not form anatomically distinct
regions when examining the drug effect on absolute
CBF. Therefore, we applied a stringent criterion of
voxelwise-corrected P<0.05 to illustrate brain regions
where increase in absolute CBF was most predomi-
nant. These peak location and cluster sizes are listed
in Table 2. Results from a simple comparison of after
time points versus before time points for each of the
drugs and the placebo sessions are presented in the
Supplementary Figure.
The most significant effects (voxelwise-corrected
P<0.05) of morphine treatment on the absolute CBF
were observed in the pregenual anterior cingulate
cortex (ACC), brainstem, cerebellum, and right
operculum (Figure 3A). Significant rCBF increases
were detected in the brainstem and cerebellum, and
significant rCBF decreases were in the putamen,
precentral gyrus, angular cortex, precuneus, tempor-
ooccipital, and frontoparietal regions (not shown in
the figures).
The most significant effects (voxelwise-corrected
P<0.05) of alcohol treatment on the absolute
CBF were observed in the precentral gyrus,
occipital pole, bilateral hippocampus, and posterior
cingulated cortex (near juxtapositional lobule)
(Figure 3B). The rCBF did not show a significant
alcohol effect.
To examine where effects of morphine and alcohol
overlap, a conjunction analysis was performed on
Figure 3 Statistical maps of regional cerebral blood flow (CBF) variations: (A) CBF increase because of morphine; (B) CBF increase
because of alcohol; (C) comparison of morphine and alcohol effects: overlapping increase in absolute CBF depicted in green;
differences in rCBF, while accounting for the placebo treatment, are depicted in hot and cool colors. See Figure 4 for quantitative
illustration.
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satisfied the criterion of t>3.2 and formed clusters at
P<0.05, depicted in green in Figure 3C. The absolute
CBF was commonly increased in the precentral,
medial occipital, cingulate, and opercular cortices.
Differences in rCBF changes of Morphinepost pre
versus Alcoholpost pre were tested in a paired t-test
(5000 permutations), whereas the subtraction effect
of Placebopost pre was included as a covariate. The
most significant differences were in the cerebellum
and the brainstem (morphine>alcohol, depicted
in hot colors), and in the precuneus, primary
sensory, and primary motor and occipitotemporal
cortices (morphine<alcohol, depicted in blue colors,
Figure 3C).
Quantitative changes in absolute and relative CBF in
ROIs: Figure 4 illustrates the quantitative CBF values
in ROIs obtained from Figure 3C.
These results illustrate the spatial heterogeneity,
and underline the sensitivity of the statistical
modeling.
The lowest variance because of treatment in DCBF
(2.3%) was in the left putamen, although the main
effects of treatment (morphine versus placebo,
alcohol versus placebo, or morphine versus alcohol)
were not significant. The main effect in the left
putamen was because of morphine-induced reduc-
tion of DrCBF from 2.5% to 15% of the global mean
CBF (95% CI).
The highest variance because of treatment in DCBF
(11.4%) was in the anterior cingulate cortex, where
DCBF was increased between 13 and 29/100ml
tissue/min after morphine; and between 2 and
19/100mltissue/min after alcohol.
The highest variance because of treatment in
DrCBF (55%) was in the right hippocampus, where
morphine reduced DrCBF within a 95% CI of 6% to
13%; and alcohol increased it within a 95% CI of 5%
to 18% of the global mean CBF. A similar effect was
also observed in the left frontoparietal network.
Opposite effects of morphine and alcohol on DrCBF
were also present in the cerebellum, where morphine
increased DrCBF by up to 7% and alcohol reduced it
between 3% and 10%.
Effects of Physiological Factors on Global and Regional
CBF
Because respiration (after morphine treatment) and
heart rate (after alcohol and placebo) were signifi-
cantly affected by treatment, their effect on variations
on global and regional CBF was examined. It has
Table 2 Summary of the effect size, cluster size, and MNI coordinates of brain locations where the highest (voxelwise-corrected
P<0.05) increase in absolute CBF and significant differences in rCBF were observed
Structure t-value No. of voxels
2 2 2mm
3
xyz
CBFMorphine (post pre)>CBFPlacebo (post pre)
Cerebellum (IX, tonsil) 5.74 3041 50 36 19
Pregenual ACC 5.31 1534 52 78 45
Right frontal operculum 5.37 529 26 73 42
Left cerebellum crus 5.03 133 58 21 15
Right temporal pole 5.12 119 28 65 16
Brainstem, pons 4.96 159 47 51 30
CBFAlcohol (post pre)>CBFPlacebo (post pre)
Left precentral 4.75 100 63 55 69
Left fusiform 4.89 75 69 51 22
Right hippocampus 4.74 72 30 42 36
Left premotor 4.94 52 57 62 70
Left cingulate cortex 4.70 50 52 52 60
Left occipital pole 4.82 45 61 15 35
Right premotor 4.60 36 39 63 67
Left prim. somatosensory 4.60 15 73 59 58
rCBFMorphine (post pre)>rCBFAlcohol (post pre)
Cerebellum 6.77 11473 29 25 11
ACC 4.53 582 47 83 39
rCBFMorphine (post pre)<rCBFAlcohol (post pre)
Left primary motor, somatosensory, and lateral occipital 5.07 2141 72 62 44
Left occipitotemporal 5.20 1257 67 32 37
Right hippocampus 5.99 1085 29 53 27
Left hippocampus 5.07 619 63 45 30
Left putamen 4.14 83 59 61 40
Left superior temporal 4.20 69 73 49 34
Right lateral occipital 4.02 62 22 31 48
ACC, anterior cingulate cortex; CBF, cerebral blood flow; MNI, Montreal Neurological Institute; rCBF, relative CBF.
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treatment can cause a hypercapnic-induced increase
in CBF (MacIntosh et al, 2008; Pattinson et al, 2007).
Also, heart rate increase because of alcohol might be
associated with vasoreactive changes that alter the
arterial blood flow velocity (Blaha et al, 2003).
Linear regression analysis indicates that lowering
of respiration rate after treatment is associated with
an increase in global CBF (slope:  0.2361±0.08444;
r=0.432, P<0.01). Effects of heart rate variation on
global CBF were more heterogeneous for different
treatments, and no significant linear relationship
was present (P>0.3) (Figure 5A).
The extent of absolute CBF changes because of
morphine became smaller, if average physiological
variables were included in the model (Figure 5B), but
no effect on the CBF changes because of alcohol was
observed (Figure 5C). Exclusion of the heart rate
covariate from the model did not change the effects
(data not shown).
Main effects of respiration and heart rate (while
effects of treatment and time are modeled) do not
satisfy any of the statistical criteria after correction
for multiple comparisons.
Placebo Effects Over Time
Our statistical tests did not reveal any relation between
the order of the visits, or treatments in preinfusion
global CBF averages (see above). However, as Figure 2C
indicates, there is a small but consistent decrease in
global CBF (average 2.5/100mltissue/min) in all but
one subject. Using a paired t-test, Placebopost and
Figure 4 Quantitative illustration of the statistically significant effects detected in ROIs: (A) absolute cerebral blood flow (CBF),
(B) relative CBF values, and (C) percentage of relative change with treatment.
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from either of the drug sessions. Results did not satisfy
the significance condition for multiple comparisons
(neither voxelwise nor cluster correction). Using a
paired t-test (degrees of freedom=11), Placebopost and
Placebopre were contrasted without including the data
from either of the drug sessions. Results did not satisfy
the significance condition for multiple comparisons
(neither voxelwise nor cluster correction). However, to
provide a preliminary explanation for the heterogeneity
of regional effects that were revealed in the later
quantitative region of interest analyses, these uncor-
rected statistical maps, thresholded at P<0.05 (uncor-
rected) for paired t-tests of absolute CBF and rCBF
changes in Placebopost versus Placebopre; Morphinepost
versus Morphinepre; and Alcoholpost versus Alcoholpre,
are illustrated in the Supplementary Figure.
Discussion
Our results indicate that PCASL is sensitive to
detecting drug-specific regional and quantifiable
changes in cerebral perfusion. Importantly, we show
that the loci of the most significant effects survive
after controlling for physiological covariates, such as
respiration depression and heart rate, which generate
global effects on cerebral perfusion. Our post hoc
quantitative analysis demonstrates how complimen-
tary information can be derived from statistical
mapping of absolute and relative changes in CBF.
We also highlight the within-subject stability of
global CBF averages before treatment and the
importance of accounting for placebo effects in
interpretation of the findings.
The primary objective of this study was methodo-
logical. Improved signal to noise ratio, improved
tagging efficiency, and higher spatial resolution
afforded by PCASL make it a desirable quantitative
and noninvasive tool in early phases of pharmaco-
logical CNS research. An ideal pharmacological tool
would be independent of any a priori assumptions
about the drug effect and would be robust to
scanning artifacts in repeated measure studies, and
to systemic physiological changes, even if these are
drug induced. Here, we minimally preprocessed the
data and used permutation testing that is indepen-
dent of assumptions about normal distribution of
Figure 5 Significant effect of respiration on cerebral blood flow (CBF). (A) A significant inverse linear relationship was present
between global changes in CBF and respiration rate, but not heart rate; (B) including respiration and heart rates as covariates in the
general linear model reduces the extent of morphine effects on absolute CBF compared with placebo (B), but has no effect on alcohol
effects on absolute CBF compared with placebo (C). Red clusters correspond to drug effects without physiological covariates in the
model. Blue clusters correspond to drug effects after including physiological covariates. For color figure see html version.
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correction for multiple comparisons were also set
independent of any region of interest or a priori
expectations. Effects of visit order or treatment on
pretreatment global average of CBF were not statis-
tically significant, suggesting that CBF is a stable
within-subject variable. Because our statistical tests
were performed nonparametrically, we did not
exclude outliers. Regardless of this ‘crude’ metho-
dology, our analysis revealed significant effects in
several brain regions that were previously reported
in the literature and will be discussed shortly.
Before interpreting neurological significance of
our findings, several methodological aspects of our
findings must be considered.
First, we detected highly localized effects within
anatomical areas, such as putamen (where rCBF
changes because of morphine were less than placebo)
and hippocampus (where absolute CBF changes
because of alcohol were greater than placebo, and
rCBF effects of morphine and alcohol were different).
This observation is noteworthy because it shows
sensitivity and anatomical specificity of PCASL to
measuring variations in subcortical perfusion. Sec-
ondly, post hoc analysis of the effect in these regions
underlines regional heterogeneity in how the cere-
bral perfusion changes. For example, conjunction
analysis on statistical parametric maps indicates
a similar increase in the absolute CBF in the right
hippocampus because of both morphine and alcohol.
In fact, quantitative ROI analysis confirms that
whereas the CBF values in this region are not
significantly different across treatments and subjects,
a significant increase of up to 12 and 17/100ml
tissue/min compared with placebo emerges after
morphine and alcohol treatments, respectively.
However, contrasting rCBF effects of morphine and
alcohol treatment shows a consistent decrease in
rCBF of the right hippocampus because of morphine
and a consistent increase of rCBF because of alcohol
(this effect was not significant when compared with
placebo), showing a significant difference in regional
effect of each drug in comparison to the rest of the
brain. However, although a significant drug by time
interaction in the putamen is detected, the main
change after alcohol or morphine is not significantly
large. In fact, effects in the left putamen come from
statistical testing of the rCBF maps. This underlines
the complementary information that statistical para-
metric mapping on absolute CBF maps and rCBF
maps provide.
Another important reason for examining the rCBF
maps is that the variance explained by them is
directly related to systemic physiological effects of
drugs on cerebral autoregulation (e.g., respiration
frequency) that affects perfusion. Here, the average
respiration rate explained 18% of variance in global
perfusion. Although we did not have data for end-
tidal CO2, or arterial CO2 tension, our results are
consistent with previous reports of a hypercapnia-
induced increase in CBF related to respiratory
depression caused by opioidergic drugs (MacIntosh
et al, 2008; Pattinson et al, 2007). As expected,
inclusion of respiration rates in our statistical model
reduced the spread of the observed effect on absolute
CBF maps, without diminishing the significance of
the peak effects of morphine. Obviously, such a
correlated physiological factor also confounds rCBF
effects (where the rCBF maps are obtained by
normalization of absolute CBF maps to global mean
CBF), which needs to be considered in interpretation
of distinct effects in rCBF maps after morphine
treatment in comparison with placebo and alcohol
treatments. For example, the observed differences in
effects of morphine and alcohol on the rCBF of the
putamen were more prominent on the left side
(Figure 3C, blue color). Pattinson and colleagues
have shown that putamen and left sensory motor
areas have an important role in motor control of
respiration, irrespective of the pharmacological
effect of an opioidergic drug (Pattinson et al, 2009).
However, MacIntosh and colleagues (MacIntosh et al,
2008) have shown that hypercapnia because
of opioidergic respiratory depression is associated
with reduced arterial transit time in the left putamen
(and insula), which they interpreted as the possible
outcome of higher arteriolar density in these
regions. Although our current data cannot sub-
stantiate either interpretation, the anatomical speci-
ficity of the treatment effects on rCBF maps
(also observed in the hippocampus, brainstem, and
cerebellum, which are important structures for
adaptation) suggests that this metric (rCBF) can
salvage important information about the neuronal
substrates of the global physiological effects of
the drug. Therefore, these various CBF metrics may
help future validation studies that aim to establish a
direct link between changes in CBF and other
factors, such as receptor activation, or event-related
potentials.
Given these methodological considerations, how
do our PCASL observations compare with previous
findings regarding the effects of these drugs?
For morphine, we observed the highest increases
in absolute CBF in the ACC, right operculum,
brainstem, and the cerebellum. PET studies with
opioidergic radiotracers have shown that the ACC,
opercular/insular cortex, thalamus, amygdala, and
putamen (the medial parts of the pain system) have
the highest (Baumgartner et al, 2006; Jones et al,
1991; Zubieta et al, 2001) and that the primary
somatosensory, sensorimotor areas (the lateral parts
of the pain system) (Baumgartner et al, 2006; Jones
et al, 1991; Zubieta et al, 2001), and occipital
areas (Sadzot et al, 1991) have the lowest binding
potentials. It has also been shown that the cerebel-
lum has spatially differential binding potential for
different subtypes of opioid receptors (Schadrack et
al, 1999). Moreover, previous perfusion studies with
opioid drugs, such as hydromorphone (Schlaepfer
et al, 1998), remifentanil (Kofke et al, 2007; Petrovic
et al, 2002; Wagner et al, 2007), and fentanyl
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regional increase in the CBF of these regions.
Notably, a bilateral reduction in rCBF because of
morphine was present in the primary sensory;
primary motor and occipitotemporal cortex, bilateral
putamen, and the right hippocampal area. Consider-
ing that the putamen has opioidergic binding
potentials comparable to the ACC (Baumgartner
et al, 2006), it is surprising that the rCBF in this
region decreases similar to the primary sensorimotor
and occipital regions with lower binding potentials.
Because a similar observation is reported in a pulsed
arterial spin labeling (PASL) study with remifentanil
and controlled respiration (Wise et al, 2010), it may
be worth noting that a simple paired t-test (albeit
uncorrected for multiple comparisons—see Supple-
mentary Figure) reveals an anatomically well-char-
acterized bilateral increase in rCBF of Placebopost
versus Placebopre, and a less extensive and more
right-lateralized decrease in rCBF of Morphinepost
versus Morphinepre and Alcoholpost versus Alco-
holpre. Although not satisfying our criteria of statis-
tical significance, they hint at an inverse relation
between rCBF changes in the putamen and the global
average changes in absolute CBF. Whether this effect
results from true cerebral activity or from regional
differences in the vascular response of the basal
ganglia deserves to be investigated.
For alcohol, the strongest effect on the absolute
CBF was in the primary sensory and primary motor
regions (more on the left side), as well as the left
temporal pole and bilateral hippocampus, where a
strong increase in absolute CBF of alcohol versus
placebo manifested. Alcohol is a depressant of
cerebral metabolism (de Wit et al, 1990; Volkow
et al, 2006, 2008; Wang et al, 2000) and it impairs
memory, visual, and motor coordination, which
seems contradictory with regional increases in the
CBF. However, frontal and temporal increase, and
cerebellar decrease in absolute CBF are also observed
in earlier placebo-controlled O
15 PET perfusion
studies (Boecker et al, 1996; Volkow et al, 1988).
Moreover, depressant effects of alcohol are not
ubiquitous. When normalizing to the global metabo-
lism, relative metabolic increases in the left temporal
lobe (Wang et al, 2000) and the ‘reward’ centers of
the brain (Volkow et al, 2008) are also reported.
Therefore, increased CBF in the hippocampus and
sensory and motor areas is plausibly related to
disinhibitory effects of alcohol on related functions
(Rose and Duka, 2007). Interestingly, post hoc
examination of the cerebellar region suggests a mild
but consistent decrease of rCBF in the cerebellum
(95% CI 3.5% to 10%) in all subjects. This is
consistent with previous reports that alcohol reduces
both the CBF (Boecker et al, 1996; Volkow et al, 1988)
and glucose metabolism (de Wit et al, 1990; Volkow
et al, 2008; Zhu et al, 2004) in the cerebellum.
However, in the same region, the rCBF was also
reduced after placebo treatment, perhaps relating to
the role of cerebellum in adaptation to environmen-
tal stimuli (such as scanner noise) over time
(Timmann et al, 1998).
A unique feature of this study is that effects of
morphine and alcohol are examined in a within-
subject crossover and placebo-controlled study,
allowing inferences about common or divergent
effects of these drugs. Here, we observed a mild
and consistent reduction of the global CBF (a least
2.5/100mL tissue/min) in the placebo session.
Although this did not produce statistically signifi-
cant regional effects, the rCBF changes because of
placebo condition were not similar in all brain
regions; for instance, DrCBF was positive in the
putamen and negative in the brainstem of most of the
participants (see Figure 4C, also the Supplementary
Figure for uncorrected t-statistic maps of comparison
Placebopost versus Placebopre). This observation raises
the possibility that psychophysiological factors such
as subject fatigue contributed to this effect, thus
emphasizing the importance of crossover experimen-
tal design. By controlling for such placebo effects, we
were able to show similar drug effects on absolute
CBF increase in the cingulate cortex, medial occipi-
tal cortex, right insula, and bilateral operculum,
perhaps reflecting common action of drugs on
opioidergic receptors (Tiihonen et al, 1994). Interest-
ingly, different effects of morphine and alcohol were
found on rCBF of the sensorimotor system (com-
prised of both primary sensory and primary motor
areas, as well as left basal ganglia and the cerebel-
lum). The overlaps and differences may relate to
similar effects of alcohol and morphine on feeling
of calmness and alertness, and different effects
on respiration, heart rate, sensation of nausea or
intoxication. In the absence of more extensive
psychometric tests, we are not able to show the
behavioral correlates of absolute or rCBF changes.
However, our findings encourage future hypotheses-
driven tests specifically examining drug effects on
functional activity of structures such as the hippo-
campus, the ACC, or the cerebellum.
In summary, we have illustrated that PCASL is
able to reveal most of the effects of alcohol and
opioids that were previously observed with PET
studies using receptor-specific, CBF, or metabolic
ligands. Research and development of drug-specific
radiotracer ligands for PET continues to provide
essential understanding of how different psycho-
active substances interact with neurotransmitter
signaling pathways. However, initial phases of drug
development require a cost-efficient, repeatable, and
generally applicable measurement tool that allows
quantifiable measurement of regional changes in
cerebral physiology. Methodologically, PCASL has
higher spatial resolution and is considerably simpler
to use in a research setting than
15O-PET. With
simple preprocessing steps, and without a priori
statistical assumptions, we illustrated anatomically
specific drug effects in a group analysis of repeated
measurements of PCASL and quantified these effects
in ROI analyses. Considering the relatively few
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of applied methodologies, we refrain from drawing
conclusions about the advantageous sensitivity of
this method compared with others. However, we
have emphasized the strength of this method in
anatomical delineation of effects in subcortical
regions such as the putamen or the hippocampus.
To be able to concretely establish the advantages of
this methodology over PET, validation studies under
similar experimental conditions must follow. We
remind that the sensitivity of our analysis can be
further improved. Currently, we have set the statis-
tical significance criteria as in blood oxygen level-
dependent studies, which did not reveal significant
effects in some of the regions where, nevertheless,
the post hoc analyses showed quantifiable effects.
Establishing PCASL-measured voxel spread-point
functions that determine the dependency of neigh-
boring voxels and the number of resolution elements
can increase statistical sensitivity of this technique.
Nonetheless, correspondence of our findings to
previously reported imaging effects of alcohol and
morphine suggests the promising potential of PCASL
in CNS drug research.
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